Skip to content

Management of melasma (dark patches on face) with unani formulation

"CLinical evaluation of topical Unani pharmacopoeial formulation Tila-e-kalf in management of kalf (melasma)" - Melasma ,ficus Carica ,prunus amygdalus

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019056
Enrollment
60
Registered
2019-05-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma Health Condition 2: L81- Other disorders of pigmentation

Interventions

Intervention1: Prunus amygdalus, Lens culinaria, Ficus carica: Powdered Prunus amygdalus and Lens culinaris with decoction of Ficus carica for local application on face for 8 weeks Control Interventi

Sponsors

Jamia Hamdard
Lead Sponsor
Dept of Moalejat
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients of all genders, belonging to 18 to 60 years age group and willing to participate in the trial voluntarily Clinically diagnosed patients of epidermal melasma using Woodâ??s lamp examination (340-400 nm) Patients willing to sign the informed consent form

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Female patient using oral contraceptives and hormonal intrauterine devices. Patients treated with tretinoin through the last 3 weeks Patients treated with hydroquinone through the last 6 months before entering the study Patients who have used any other bleaching creams or topical steroid creams for at least 4 weeks before entering the study Patients who undergone any laser therapies and chemical peeling Having used or consuming photosensitizing substances in past 4 weeks Patients with drug or alcohol addiction Patient having any endocrine or auto-immune disease Patients with Diabetes mellitus, renal insufficiency, severe liver, spleen, or heart diseases

Design outcomes

Primary

MeasureTime frame
MASI Index, Melasma QoL Index, PGATimepoint: 2 weeks, 4 weeks, 6 weeks, 8 weeks

Secondary

MeasureTime frame
CBC, LFT, KFT, Urine (R/M)Timepoint: 0 day, 14th day, 56th day

Countries

India

Contacts

Public ContactDr Sadia Nikhat

Jamia Hamdard

yshamsi@jamiahamdard.ac.in8750040776

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026